Abstract: A molecular sensor of an embodiment includes a sensitive film including a plurality of metal organic framework particles, and a detector configured to be capable of measuring a change in physical quantity due to adsorption of a target molecule to the sensitive film. Pores are present between the plurality of metal organic framework particles, and the pores are any of mesopores of 2 nm or more and 50 nm or less, micropores smaller than the mesopores, and macropores larger than the mesopores. A sum of areas of the micropores is defined as Smi, a sum of areas of the mesopores is defined as Sme, a sum of areas of the macropores is defined as Sma, and an area of an entire image analysis area is defined as Stotal, in an image analysis area by two-dimensional image analysis on a cross section of the sensitive film in a thickness direction. Pore distribution satisfies 0.35?Sme/(Smi+Sme+Sma), 0.01?Smi+Sme+Sma)/Stotal?0.5.

Abstract: A molecular sensor includes: a base; and a sensitive film provided above the base and containing a metal organic framework and a hydrophobic polymer, a contact angle respect to water of the hydrophobic polymer being larger than that of the metal organic framework. The metal organic framework is on the base side of the sensitive film, and the hydrophobic polymer is above the metal organic framework in the sensitive film.

Abstract: By combining a compound having RET kinase inhibitory activity with a CDK4/6 inhibitor, the present inventors have found a drug, a combination, a pharmaceutical composition, and a preparation which are effective for treating or preventing cancer, a method for treating or preventing cancer, or a method for suppressing tumor growth.

Abstract: The invention provides a reshaped human anti-HM 1.24 antibody having: (A) an L chain having (1) the C region of a human L chain, and (2) the V region of an L chain having the FR of a human L chain and the CDR of the L chain of a mouse anti-HM 1.24 monoclonal antibody; and (B) an H chain having (1) the C region of a human H chain, and (2) the V region of an H chain having the FR of a human H chain and the CDR of the H chain of a mouse anti-HM 1.24 monoclonal antibody. This reshaped human antibody is derived from human antibody and the CDR has a low antigenicity, and the reshaped human antibody of the present invention has a low antigenicity and can be used for medical treatment.

Abstract: The system for managing materials comprises: a material yard which has a material carry-in port and a material carry-out port, the material yard being divided into a plurality of yard sections which store materials; a plurality of first tags which record data of the materials to be read in a non-contact manner, the first tags being attached to the materials managed in the material yard; a second tag which stores and sends data of an identification ID issued for each of lots into which the materials are classified to check a current position of each of the lots via a position sensing signal transmitted to the material yard, the second tag being attached to each of the lots; a reading device which reads the data recorded in the first tags, the reading device being provided in at least one of the material carry-in port and the material carry-out port within the material yard; a plurality of receiving devices which receive a data signal of the identification ID transmitted from the second tag, the receiving devic

Abstract: The system for managing materials comprises: a material yard which has a material carry-in port and a material carry-out port, the material yard being divided into a plurality of yard sections which store materials; a plurality of first tags which record data of the materials to be read in a non-contact manner, the first tags being attached to the materials managed in the material yard; a second tag which stores and sends data of an identification ID issued for each of lots into which the materials are classified to check a current position of each of the lots via a position sensing signal transmitted to the material yard, the second tag being attached to each of the lots; a reading device which reads the data recorded in the first tags, the reading device being provided in at least one of the material carry-in port and the material carry-out port within the material yard; a plurality of receiving devices which receive a data signal of the identification ID transmitted from the second tag, the receiving devic

Abstract: A reshaped human anti-HM 1.24 antibody comprising: (A) an L chain comprising (1) the C region of a human L chain, and (2) the V region of an L chain comprising the FR of a human L chain and the CDR of the L chain of a mouse anti-HM 1.24 monoclonal antibody; and (B) an H chain comprising (1) the C region of a human H chain, and (2) the V region of an H chain comprising the FR of a human H chain and the CDR of the H chain of a mouse anti-HM 1.24 monoclonal antibody. Since most of this reshaped human antibody is derived from human antibody and the CDR has a low antigenicity, the reshaped human antibody of the present invention has a low antigenicity and, therefore, is expected to be-used for medical treatment.

Abstract: A reshaped human anti-HM 1.

Abstract: A therapeutic agent for lymphatic tumors (excluding myeloma) comprising as an active ingredient an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity.

Abstract: A reshaped human anti-HM 1.

Abstract: A therapeutic agent for lymphatic tumors (excluding myeloma) comprising as an active ingredient an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO:1 and SEQ ID NO:5 and that has a cytotoxic activity.

Abstract: A therapeutic agent for lymphatic tumors (excluding myeloma) comprising as an active ingredient an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity.

Abstract: In a method of preparing a diffused silicon device substrate for use in the fabrication of a MOS power device, a drive-in diffusion step is followed by a thermal donor formation heat treatment which is achieved by heating the silicon device substrate at a temperature from 400.degree. to 500.degree. C. for 1 to 20 hours and in a gas atmosphere containing oxygen gas, and subsequently a thermal donor formation retarding heat treatment is performed by heating the silicon device substrate at a temperature of from 600.degree. to 700.degree. C. for 8 to 24 hours in a gas atmosphere containing oxygen gas.

Abstract: The present invention provides dihydropyridine derivatives represented by the following formula (I) ##STR1## and salts thereof. They have extremely strong, slow and long-acting vasodilating action and antihypertensive action with less adverse effects so that they are useful as therapeutic agents for cardiovascular diseases.

Abstract: The present invention provides dihydropyridine derivatives represented by the following formula (I) ##STR1## and salts thereof. They have extremely strong, slow and long-acting vasodilating action and antihypertensive action with less adverse effects so that they are useful as therapeutic agents for cardiovascular diseases.

Abstract: It is known that it is advantageous in semiconductor wafer production to re-slice a semiconductor wafer having impurity diffusion layers on both sides which are processed or doped in advance of the re-slicing process. In the re-slicing process, a thin slice base is mounted on the periphery of a semiconductor wafer prior to the re-slicing process for protecting the periphery of the wafer from chipping off damage during the re-slicing process by an ID saw or the like. The present invention provides several examples of methods and apparatus for mounting a slice base prepared in advance on the periphery of a semiconductor wafer by utilizing the method and apparatus of the present invention. In addition, another method and apparatus for simultaneously molding and mounting a molded type slice base by using a thermosetting type resin on the periphery of the semiconductor, whereby the re-slicing process of a semiconductor wafer is extremely improved in production and labor cost.

Abstract: An electronic noise attenuation system for attenuating a sound wave propagated from a source of noise by generating another sound wave 180.degree. out of phase and having the same sound pressure with the propagated sound wave from electro-mechanic transducer means disposed in a propagation passage of sound waves. In the electronic noise attenuation system, a drive signal for drive the electro-mechanic transducer means is generated in accordance with output signals respectively output from upstream-side and downstream-side mechano-electric transducer means respectively disposed in the propagation passage with the electro-mechanic transducer means therebetween. Namely, the drive signal is created by performing an operation on a difference signal between the output signal of the upstream mechano-electric transducer means and the drive signal according to a given transfer function.